Supernus Pharmaceuticals Debt to Equity Ratio 2011-2023 | SUPN
Current and historical debt to equity ratio values for Supernus Pharmaceuticals (SUPN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Supernus Pharmaceuticals debt/equity for the three months ending December 31, 2023 was 0.00.
| Supernus Pharmaceuticals Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-12-31 |
$0.36B |
$0.92B |
0.39 |
| 2023-09-30 |
$0.37B |
$0.91B |
0.41 |
| 2023-06-30 |
$0.37B |
$0.92B |
0.41 |
| 2023-03-31 |
$0.88B |
$0.91B |
0.96 |
| 2022-12-31 |
$0.82B |
$0.89B |
0.92 |
| 2022-09-30 |
$0.84B |
$0.85B |
0.99 |
| 2022-06-30 |
$0.85B |
$0.84B |
1.01 |
| 2022-03-31 |
$0.81B |
$0.83B |
0.98 |
| 2021-12-31 |
$0.87B |
$0.82B |
1.07 |
| 2021-09-30 |
$0.75B |
$0.81B |
0.92 |
| 2021-06-30 |
$0.79B |
$0.79B |
1.00 |
| 2021-03-31 |
$0.75B |
$0.75B |
1.00 |
| 2020-12-31 |
$0.76B |
$0.75B |
1.02 |
| 2020-09-30 |
$0.80B |
$0.71B |
1.13 |
| 2020-06-30 |
$0.83B |
$0.67B |
1.24 |
| 2020-03-31 |
$0.58B |
$0.61B |
0.94 |
| 2019-12-31 |
$0.57B |
$0.60B |
0.95 |
| 2019-09-30 |
$0.55B |
$0.56B |
0.99 |
| 2019-06-30 |
$0.54B |
$0.52B |
1.03 |
| 2019-03-31 |
$0.55B |
$0.48B |
1.14 |
| 2018-12-31 |
$0.53B |
$0.45B |
1.16 |
| 2018-09-30 |
$0.50B |
$0.42B |
1.19 |
| 2018-06-30 |
$0.46B |
$0.39B |
1.18 |
| 2018-03-31 |
$0.47B |
$0.35B |
1.35 |
| 2017-12-31 |
$0.16B |
$0.27B |
0.59 |
| 2017-09-30 |
$0.13B |
$0.25B |
0.53 |
| 2017-06-30 |
$0.12B |
$0.23B |
0.51 |
| 2017-03-31 |
$0.12B |
$0.21B |
0.56 |
| 2016-12-31 |
$0.12B |
$0.19B |
0.61 |
| 2016-09-30 |
$0.11B |
$0.17B |
0.65 |
| 2016-06-30 |
$0.11B |
$0.11B |
0.98 |
| 2016-03-31 |
$0.10B |
$0.10B |
1.00 |
| 2015-12-31 |
$0.10B |
$0.09B |
1.14 |
| 2015-09-30 |
$0.09B |
$0.08B |
1.12 |
| 2015-06-30 |
$0.08B |
$0.07B |
1.14 |
| 2015-03-31 |
$0.08B |
$0.06B |
1.19 |
| 2014-12-31 |
$0.10B |
$0.04B |
2.36 |
| 2014-09-30 |
$0.09B |
$0.04B |
2.49 |
| 2014-06-30 |
$0.06B |
$0.03B |
1.82 |
| 2014-03-31 |
$0.07B |
$0.03B |
2.36 |
| 2013-12-31 |
$0.08B |
$0.03B |
2.32 |
| 2013-09-30 |
$0.11B |
$0.01B |
8.94 |
| 2013-06-30 |
$0.10B |
$0.04B |
2.68 |
| 2013-03-31 |
$0.04B |
$0.04B |
0.92 |
| 2012-12-31 |
$0.04B |
$0.06B |
0.63 |
| 2012-09-30 |
$0.04B |
$0.03B |
1.72 |
| 2012-06-30 |
$0.04B |
$0.04B |
1.11 |
| 2012-03-31 |
$0.04B |
$0.00B |
156.67 |
| 2011-12-31 |
$0.04B |
$0.01B |
4.69 |
| 2011-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2011-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2011-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2010-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.604B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
